The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Eli Lilly said its phase 3 trial of GLP-1 drug in pill form found results similar to popular injectables for weight loss. Orforglipron would be used as a daily pill, eliminating the need for ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

“There is some evidence that there is altered brain activity related to reward-related behaviors, including appetite and ...

Eli Lilly's Phase 3 study highlights the effectiveness of Orforglipron in lowering blood sugar and promoting weight loss, potentially offering a convenient alternative to GLP-1 injections.

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

As a large proportion of people taking medications like Mounjaro, Ozempic and Wegovy for weight loss report consuming less processed foods and soda, researchers say food and beverage companies are ...

What is our current understanding of how differences in sex can affect obesity prevalence, comorbidities, and treatment options?